{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Intravitreal+Injections", "query": { "condition": "Intravitreal Injections" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 256, "total_pages": 26, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Intravitreal+Injections&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-22T07:36:47.222Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03203447", "title": "Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Macular Edema", "Retinal Vein Occlusion" ], "interventions": [ { "name": "suprachoroidal CLS-TA", "type": "DRUG" }, { "name": "suprachoroidal sham", "type": "DRUG" }, { "name": "Lucentis or Avastin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Clearside Biomedical, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 325, "start_date": "2018-03-05", "completion_date": "2018-12-18", "has_results": true, "last_update_posted_date": "2021-04-23", "last_synced_at": "2026-07-22T07:36:47.222Z", "location_count": 72, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 61 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Arcadia", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03203447" }, { "nct_id": "NCT02555306", "title": "A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Age-Related Macular Degeneration" ], "interventions": [ { "name": "0.5 mg of DE-122", "type": "DRUG" }, { "name": "1.0 mg of DE-122", "type": "DRUG" }, { "name": "2.0 mg of DE-122", "type": "DRUG" }, { "name": "4.0 mg of DE-122", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Santen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 12, "start_date": "2015-09-16", "completion_date": "2017-08", "has_results": true, "last_update_posted_date": "2020-01-14", "last_synced_at": "2026-07-22T07:36:47.222Z", "location_count": 5, "location_summary": "Mountain View, California • Walnut Creek, California • Jackson, Michigan + 2 more", "locations": [ { "city": "Mountain View", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Jackson", "state": "Michigan" }, { "city": "Austin", "state": "Texas" }, { "city": "McAllen", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02555306" }, { "nct_id": "NCT01521559", "title": "Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Branch Retinal Vein Occlusion" ], "interventions": [ { "name": "Macular Laser Photocoagulation", "type": "PROCEDURE" }, { "name": "Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 183, "start_date": "2012-04", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2014-11-13", "last_synced_at": "2026-07-22T07:36:47.222Z", "location_count": 45, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 42 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Mountain View", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01521559" }, { "nct_id": "NCT06864988", "title": "4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Macular Neovascularization Secondary to Age-Related Macular Degeneration" ], "interventions": [ { "name": "4D-150 IVT (3E10 vg/eye)", "type": "BIOLOGICAL" }, { "name": "EYLEA® (aflibercept) Injection 2 mg (0.05mL)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "4D Molecular Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 480, "start_date": "2025-03-03", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-07-22T07:36:47.222Z", "location_count": 91, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Springdale, Arkansas + 79 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06864988" }, { "nct_id": "NCT06373731", "title": "ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Age Related Macular Degeneration (ARMD)" ], "interventions": [ { "name": "Elamipretide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stealth BioTherapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": null, "sex": "ALL", "summary": "55 Years and older" }, "enrollment_count": 313, "start_date": "2024-05-30", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-07-22T07:36:47.222Z", "location_count": 31, "location_summary": "Phoenix, Arizona • Sun City, Arizona • Huntington Beach, California + 28 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Poway", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06373731" }, { "nct_id": "NCT01573572", "title": "Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Age-Related Macular Degeneration", "Retinal Vein Occlusion", "Diabetic Macular Edema" ], "interventions": [ { "name": "pegaptanib sodium injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bausch & Lomb Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 131, "start_date": "2010-04-22", "completion_date": "2019-11-14", "has_results": true, "last_update_posted_date": "2021-01-08", "last_synced_at": "2026-07-22T07:36:47.222Z", "location_count": 4, "location_summary": "Murrieta, California • Marshalltown, Iowa • West Mifflin, Pennsylvania + 1 more", "locations": [ { "city": "Murrieta", "state": "California" }, { "city": "Marshalltown", "state": "Iowa" }, { "city": "West Mifflin", "state": "Pennsylvania" }, { "city": "Harlingen", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01573572" }, { "nct_id": "NCT04343222", "title": "Control of Pain in Intravitreal Injections Using Topical NSAIDs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Intravitreal Injections", "IVI" ], "interventions": [ { "name": "Bromfenac", "type": "DRUG" }, { "name": "Artificial tears", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2019-06-27", "completion_date": "2019-12-19", "has_results": true, "last_update_posted_date": "2023-06-12", "last_synced_at": "2026-07-22T07:36:47.222Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04343222" }, { "nct_id": "NCT03211234", "title": "Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Age-Related Macular Degeneration" ], "interventions": [ { "name": "2.0 mg DE-122 Injectable Solution + Lucentis", "type": "DRUG" }, { "name": "4.0 mg DE-122 Injectable Solution + Lucentis", "type": "DRUG" }, { "name": "Lucentis", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Santen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 76, "start_date": "2017-07-05", "completion_date": "2020-01-31", "has_results": true, "last_update_posted_date": "2021-07-13", "last_synced_at": "2026-07-22T07:36:47.222Z", "location_count": 10, "location_summary": "Gilbert, Arizona • Beverly Hills, California • Mountain View, California + 7 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Mountain View", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Golden", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03211234" }, { "nct_id": "NCT03630952", "title": "Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neovascular Age-related Macular Degeneration" ], "interventions": [ { "name": "0.5 mg Conbercept Intravitreal Injection", "type": "BIOLOGICAL" }, { "name": "1.0 mg Conbercept Intravitreal Injection", "type": "BIOLOGICAL" }, { "name": "2.0 mg Aflibercept Intravitreal Injection", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Chengdu Kanghong Biotech Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 1157, "start_date": "2018-12-21", "completion_date": "2021-05-19", "has_results": false, "last_update_posted_date": "2021-06-23", "last_synced_at": "2026-07-22T07:36:47.222Z", "location_count": 69, "location_summary": "Phoenix, Arizona • Springdale, Arkansas • Arcadia, California + 61 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Arcadia", "state": "California" }, { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03630952" }, { "nct_id": "NCT05282004", "title": "Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neovascular Age-related Macular Degeneration (nAMD)" ], "interventions": [ { "name": "SOK583A1", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sandoz", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 36, "start_date": "2022-05-16", "completion_date": "2022-09-07", "has_results": true, "last_update_posted_date": "2023-05-10", "last_synced_at": "2026-07-22T07:36:47.222Z", "location_count": 5, "location_summary": "Poway, California • Marietta, Georgia • Oak Forest, Illinois + 2 more", "locations": [ { "city": "Poway", "state": "California" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Oak Forest", "state": "Illinois" }, { "city": "Liverpool", "state": "New York" }, { "city": "Lynchburg", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05282004" } ] }